Vergelijking

TB-500 vs. Thymosin Beta-4

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Genezing

CAS-nr.

geen gegevens

77591-33-4

Molecuulmassa

888 g/mol

4921 g/mol

Halfwaardetijd

geen gegevens

Sequentie

Ac-LKKTETQ

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

Werkingsmechanisme

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Thymosin Beta-4

Thymosin Beta-4 forms a 1:1 complex with monomeric (G-)actin and is regarded as the principal actin-sequestering factor in many cell types, thereby influencing cytoskeletal dynamics and directional cell migration. Preclinical models additionally describe effects on endothelial cell migration and neovascularisation, as well as activation of survival signalling pathways (including ILK/Akt). The mechanistic evidence derives predominantly from cell-culture and animal models.

Bewijsbasis

Hoogste bewijs

Diermodel

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	TB-500	Thymosin Beta-4
Australië	Verboden	—
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Alleen onderzoek	Niet goedgekeurd

Volledige vermeldingen

TB-500

Volledige vermelding →

Thymosin Beta-4

Volledige vermelding →

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?: TB-500 is classified as "Genezing", while Thymosin Beta-4 is classified as "Genezing". TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, TB-500 or Thymosin Beta-4?: The highest available evidence level is "Diermodel" for TB-500 and "Humane studie" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of TB-500 and Thymosin Beta-4 in Germany and the United States?: Duitsland: TB-500 — Niet goedgekeurd, Thymosin Beta-4 — Niet goedgekeurd. Verenigde Staten: TB-500 — Alleen onderzoek, Thymosin Beta-4 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

TB-500

Thymosin Beta-4

Australië

Verboden

—

Duitsland

Niet goedgekeurd

Verenigde Staten

Alleen onderzoek

Niet goedgekeurd

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?

TB-500 is classified as "Genezing", while Thymosin Beta-4 is classified as "Genezing". TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, TB-500 or Thymosin Beta-4?

The highest available evidence level is "Diermodel" for TB-500 and "Humane studie" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of TB-500 and Thymosin Beta-4 in Germany and the United States?

Duitsland: TB-500 — Niet goedgekeurd, Thymosin Beta-4 — Niet goedgekeurd. Verenigde Staten: TB-500 — Alleen onderzoek, Thymosin Beta-4 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.